RT Journal Article
SR Electronic
T1 Machine Learning to Understand Genetic and Clinical Factors Associated with the Pulse Waveform Dicrotic Notch
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.09.21267484
DO 10.1101/2021.12.09.21267484
A1 Cunningham, Jonathan W.
A1 Achille, Paolo Di
A1 Morrill, Valerie N.
A1 Weng, Lu-Chen
A1 Choi, Seung Hoan
A1 Khurshid, Shaan
A1 Nauffal, Victor
A1 Pirruccello, James P
A1 Solomon, Scott D.
A1 Batra, Puneet
A1 Ho, Jennifer E.
A1 Philippakis, Anthony A.
A1 Ellinor, Patrick T.
A1 Lubitz, Steven A.
YR 2021
UL http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267484.abstract
AB Background Absence of a dicrotic notch on finger photoplethysmography (PPG) is an easily ascertainable and inexpensive trait that has been associated with age and prevalent cardiovascular disease (CVD). However, the trait exists along a continuum, and little is known about its genetic underpinnings or prognostic value for incident CVD.Methods In 169,787 participants in the UK Biobank, we identified absent dicrotic notch on PPG and created a novel continuous trait reflecting notch smoothness using machine learning. Next, we determined the heritability, genetic basis, polygenic risk, and clinical relations for the binary absent notch trait and the newly derived continuous notch smoothness trait.Results Heritability of the continuous notch smoothness trait was 7.5%, compared with 5.6% for the binary absent notch trait. A genome wide association study of notch smoothness identified 15 significant loci, implicating genes including NT5C2 (P=1.2×10−26), IGFBP3 (P=4.8×10−18), and PHACTR1 (P=1.4×10−13), compared with 6 loci for the binary absent notch trait. Notch smoothness stratified risk of incident myocardial infarction or coronary artery disease, stroke, heart failure, and aortic stenosis. A polygenic risk score for notch smoothness was associated with incident CVD and all-cause death in UK Biobank participants without available PPG data.Conclusion We found that a machine learning derived continuous trait reflecting dicrotic notch smoothness on PPG was heritable and associated with genes involved in vascular stiffness. Greater notch smoothness was associated with greater risk of incident CVD. Raw digital phenotyping may identify individuals at risk for disease via specific genetic pathways.Competing Interest StatementDr. Di Achille and Dr. Batra are supported by grants from Bayer AG and IBM applying machine learning in cardiovascular disease. Dr. Weng receives sponsored research support from IBM to the Broad Institute. Dr. Pirruccello . has served as a consultant for Maze Therapeutics and has received research support from IBM Research. Dr. Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Celladon, Gilead, GlaxoSmithKline, Ionis Pharmaceutics, Lone Star Heart, Mesoblast, MyoKardia, NIH/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos and has consulted for Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Corvia, Gilead, GlaxoSmithKline, Ironwood, Merck, Novartis, Pfizer, Takeda, and Theracos. Dr. Batra serves as a consultant for Novartis and Prometheus Biosciences. Dr. Ellinor receives sponsored research support from Bayer AG, Novartis, Myokardia and Quest. Dr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, Fitbit, and IBM, and has consulted for Bristol Myers Squibb / Pfizer, Bayer AG, and Blackstone Life Sciences. The remaining authors have no disclosures.Funding StatementDr. Weng is supported by NIH grant 1R01HL139731 and American Heart Association Postdoctoral fellowship 18SFRN34110082. Dr. Nauffal is funded by a training grant from the NIH (T32HL007604). Dr. Pirruccello is supported by a Scholar award from the Sarnoff Cardiovascular Research Foundation and by the NIH (K08HL159346). Dr. Ho is supported by the NIH (R01 HL134893, R01 HL140224, and K24 HL153669). Dr. Ellinor is supported by the NIH (1R01HL092577, K24HL105780), AHA (18SFRN34110082), Foundation Leducq (14CVD01), and by MAESTRIA (965286). Dr. Lubitz is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from the UK Biobank (https://www.ukbiobank.ac.uk/). All participants provided written informed consent. The UK Biobank was approved by the UK Biobank Research Ethics Committee (reference# 11/NW/0382). Use of UK Biobank data (application 17488) was approved by the local Mass General Brigham Health Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study involves only openly available human data, which can be obtained from the UK Biobank (https://www.ukbiobank.ac.uk/)